Haemonetics Corp. Watch

from 8-K 35 pages [Dealer] [ ] [ ] Attention: [ ] Telephone No.: [ ] Facsimile No.: [ ] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Michelle Basil, General Counsel Telephone No.: Email: From: Re: Additional Call Option Transaction Date: May 23, 2024 Dear Ladies and Gentlemen

from 8-K 34 pages [Dealer] [ ] [ ] Attention: [ ] Telephone No.: [ ] Facsimile No.: [ ] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Michelle Basil, General Counsel Telephone No.: Email: From: Re: Base Call Option Transaction Date: May 22, 2024 Dear Ladies and Gentlemen

from 10-K 3 pages Addenda No 2 Adresse Des Lieux Loues 750, Boulevard Du Parc Technologique Québec (Québec) G1p 4s3

from 10-K 6 pages [Addenda No 1] Adresse Des Lieux Loues 750, Boulevard Du Parc Technologique Québec (Québec) G1p 4s3

from 10-K 24 pages Bail Entre 1405 Ptqm (SEC) (CI-Après Le « Bailleur ») Et Opsens Inc. (CI-Après Le « Locataire ») Adresse Des Lieux Loues : 750,.boulevard Du Parc Technologique Québec (Québec) G1p 4s3 Échéance Du Terme Du Bail ; 30 Septembre·2025

from 10-Q 44 pages Office Lease Agreement

from 10-Q 9 pages Certain Information Has Been Omitted From This Document Because It Is Not Material, Is the Type That Haemonetics Corporation Treats as Confidential and Would Be Competitively Harmful if Publicly Disclosed. Omissions Are Marked [***]

from 8-K/A 14 pages Certain Information Has Been Omitted From This Document Because It Is Not Material, Is the Type That Haemonetics Corporation Treats as Confidential and Would Be Competitively Harmful if Publicly Disclosed. Omissions Are Marked [***]. Voting Support Agreement

from 10-Q 10 pages Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan Performance Share Unit Award Agreement

from 10-Q 6 pages Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan Nonqualified Stock Option Award Agreement

from 10-Q 6 pages Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan Restricted Stock Unit Award Agreement

from 10-Q 10 pages Haemonetics Corporation Worldwide Employee Bonus Plan

from 8-K 21 pages Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan

from 10-Q 7 pages Amendment II to Shelter Plan Service Agreement Dated June 10, 2014

from 10-Q 10 pages 1.continued Service and Transition as Executive Vice President and General Counsel. Your Service as Executive Vice President and General Counsel of the Company Will Continue Until October 31, 2022 (The “Retention Date”). Your Service as an Employee With the Company Will End on the Retention Date. for Avoidance of Doubt, the Termination of Your Employment on the Retention Date, Under the Terms of This Agreement, Is Not a Qualifying Termination Under the Executive Severance Agreement Between You and the Company Dated November 7, 2017 (The “Executive Severance Agreement”). 2. Compensation and Retention Payment. A.SALARY. From Now Until the Retention Date (The “Transition Period”), You Will Continue to Receive Your Current Salary, Provided That Your Employment Does Not Earlier Terminate. B.ANNUAL Bonus. You Will Not Be Eligible to Receive an Annual Bonus for Fiscal 2023 as You Will No Longer Be an Employee of the Company Subsequent to the Retention Date

from 10-Q 10 pages Certain Information Has Been Omitted From This Document Because It Is (I) Not Material, and (II) Would Be Competitively Harmful if Publicly Disclosed. Omissions Are Marked [***]

from 10-Q 11 pages This Retention and Transition Agreement (This “Agreement”) Sets Forth the Understanding Between You and Haemonetics Corporation (The “Company”) Regarding Your Continued Employment as Chief Financial Officer of the Company and Your Planned Retirement From the Company and Transition. on Behalf of the Board of Directors of the Company, I Want to Thank You for Your Willingness to Provide Continued Service as Chief Financial Officer and Then in the Role of Special Advisor as Provided in This Agreement in Order to Ensure a Seamless and Successful Transition to the Next Chief Financial Officer of the Company. 1. Continued Service as Chief Financial Officer and Special Advisor

from 10-Q 6 pages Fourteenth Amendment to Agreement of Lease Dated This 11th Day of November, 2021 by and Between

from 8-K 33 pages [ ] [ ] [ ] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Telephone No.: Email: From: Re: Additional Call Option Transaction Date: March 12, 2021 Dear Ladies and Gentlemen

from 8-K 33 pages [ ] [ ] [ ] To: Haemonetics Corporation 125 Summer Street Boston, Massachusetts 02110 Attention: Telephone No.: Email: From: Re: Base Call Option Transaction Date: March 2, 2021 Dear Ladies and Gentlemen